Redwood Pharma AB: Year-end report January – December 2019
1 January – 31 December 2019 · Net revenue for the period was SEK 0 (0). · Operating loss for the period amounted to SEK -15.758 million (-13.969 million). · Loss per share for the period was SEK -1.07 (-1.25). Fourth quarter, 1 October – 31 December 2019 · Net revenue for the period was SEK 0 (0). · Operating loss for the period amounted to SEK -3.834 million (-3.019 million). · Loss per share for the period was SEK -0.30 (-0.25). Important events during the period · Redwood Pharma completed the treatment phase of Phase II clinical trials of R101. The first